Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
GAITHERSBURG, Md., March 30, 2016 -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in Needham & Company’s 15th Annual Healthcare Conference, April 12-13, 2016 in New York, NY.
Presentation date and time will be updated on the Emergent website www.emergentbiosolutions.com under “Investors” as this information becomes available.
For this conference, the company will be webcasting its presentation, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcast will be available both live and by replay, accessible from the Emergent website www.emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions Inc.
Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Tracey Schmitt Lintott Senior Vice President, Global Public Affairs 240-631-3394 [email protected]
